

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

February 2010

Vol. 38, No. 2

CONTENTS

SHORT COMMUNICATION

- Genetic Variants of *CYP3A4* and *CYP3A5* in Cynomolgus and Rhesus Macaques. *Yasuhiro Uno, Akinori Matsushita, Naoki Osada, Shotaro Uehara, Sakae Kohara, Ryoichi Nagata, Koichiro Fukuzaki, Masahiro Utoh, Norie Murayama, and Hiroshi Yamazaki* **209**

ARTICLES

- Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans. *Takao Watanabe, Hiroyuki Kusuhara, Kazuya Maeda, Hiroshi Kanamaru, Yoshikazu Saito, Zhuohan Hu, and Yui-chi Sugiyama* **215**

- Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance. *Liyue Huang, Loren Berry, Sindhura Ganga, Brett Janosky, April Chen, Jonathan Roberts, Adria E. Colletti, and Min-Hwa Jasmine Lin* **223**

- Coupling of Liquid Chromatography/Tandem Mass Spectrometry and Liquid Chromatography/Solid-Phase Extraction/NMR Techniques for the Structural Identification of Metabolites following In Vitro Biotransformation of SUR1-Selective ATP-Sensitive Potassium Channel Openers. *Florian Gillotin, Patrice Chiap, Michel Frédérick, Jean-Claude Van Heugen, Pierre Francotte, Philippe Lebrun, Bernard Pirotte, and Pascal de Tullio* **232**

- Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. *Sara K. Quinney, Xin Zhang, Aroonrut Lucksiri, J. Christopher Gorski, Lang Li, and Stephen D. Hall* **241**

- Time-Dependent Inhibitory Effects of (1*R*,9*S*,12*S*,13*R*,14*S*,17*R*,18*E*,21*S*,23*S*,24*R*,25*S*,27*R*)-1,14-Dihydroxy-12-(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetrone (FK1706), a Novel Nonimmunosuppressive Immunophilin Ligand, on CYP3A4/5 Activity in Humans in Vivo and in Vitro. *Tsuyoshi Minematsu, Jennifer Lee, Jiuhong Zha, Selina Moy, Donna Kowalski, Katsuyuki Hori, Koji Ishibashi, Takashi Usui, and Hidetaka Kamimura* **249**

- If the K_1 Is Defined by the Free Energy of Binding to P-Glycoprotein, Which Kinetic Parameters Define the IC_{50} for the Madin-Darby Canine Kidney II Cell Line Overexpressing Human Multidrug Resistance 1 Confluent Cell Monolayer? *Annie Albin Lumen, Poulomi Acharya, Joseph W. Polli, Andrew Ayrton, Harma Ellens, and Joe Bentz* **260**

- Inhibition of Intestinal and Hepatic Glucuronidation of Mycophenolic Acid by *Ginkgo biloba* Extract and Flavonoids. *Mohamed-Eslam F. Mohamed and Reginald F. Frye* **270**

- An In Vitro Assay to Assess Transporter-Based Cholestatic Hepatotoxicity Using Sandwich-Cultured Rat Hepatocytes. *John H. Ansele, William R. Smith, Cassandra H. Perry, Robert L. St. Claire III, and Kenneth R. Brouwer* **276**

- Isolation and Identification of Urinary Metabolites of Kakkalide in Rats. *Xue Bai, Yuanyuan Xie, Jia Liu, Jialin Qu, Yoshihiro Kano, and Dan Yuan* **281**

- In Vivo Bioavailability, Absorption, Excretion, and Pharmacokinetics of [¹⁴C]Procyanidin B2 in

Continued on next page

Male Rats. <i>Stavroula Stoupi, Gary Williamson, Florian Viton, Denis Barron, Laurence J. King, Jonathan E. Brown, and Michael N. Clifford</i> . . .	287	Development of a Novel System for Estimating Human Intestinal Absorption Using Caco-2 Cells in the Absence of Esterase Activity. <i>Kayoko Ohura, Hisae Sakamoto, Shin-ichi Ninomiya, and Teruko Imai</i>	323
[S] Species Differences in the Biotransformation of an $\alpha_4\beta_2$ Nicotinic Acetylcholine Receptor Partial Agonist: The Effects of Distinct Glucuronide Metabolites on Overall Compound Disposition. <i>Christopher L. Shaffer, Mithat Gunduz, Tim F. Ryder, and Thomas N. O'Connell</i>	292	[S] Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of Defect. <i>Christopher C. Marohnic, Satya P. Panda, Karen McCammon, José Rueff, Bettie Sue Siler Masters, and Michel Kranendonk</i>	332
A Single Amino Acid Substitution Confers High Cinchonidine Oxidation Activity Comparable with That of Rabbit to Monkey Aldehyde Oxidase 1. <i>Kensuke Fukiya, Kunio Itoh, Satoshi Yamaguchi, Akiko Kishiba, Mayuko Adachi, Nobuaki Watanabe, and Yori-hisa Tanaka</i>	302	Expression and Localization of Rat Aldo-Keto Reductases and Induction of the 1B13 and 1D2 Isoforms by Phenolic Antioxidants. <i>A. Kenneth MacLeod, Vincent P. Kelly, Larry G. Higgins, Michael O. Kelleher, Sally A. Price, Alison L. Bigley, Graham R. Betton, and John D. Hayes</i>	341
A Comparison of Pharmacokinetics between Humans and Monkeys. <i>Takafumi Akabane, Kenji Tabata, Keitaro Kadono, Shuichi Sakuda, Shigeyuki Terashita, and Toshio Teramura</i>	308	Identification of Novel Substrates for Human Cytochrome P450 2J2. <i>Caroline A. Lee, David Neul, Andrea Clouser-Roche, Deepak Dalvie, Michael R. Wester, Ying Jiang, J. P. Jones III, Sascha Freiwald, Michael Zientek, and Rheem A. Totah</i>	347
The Effect of Ethanol on Oral Cocaine Pharmacokinetics Reveals an Unrecognized Class of Ethanol-Mediated Drug Interactions. <i>Robert B. Parker and S. Casey Laizure</i>	317		

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Comparison between the active site cavity volumes for human CYP2J2, CYP3A4 active sites and overlay of CYP2J2 and CYP3A4. See the article by Lee et al. on page 347 of this issue.